It is believed that men diagnosed with prostate cancer and a low baseline serum testosterone (BST) may have more aggressive disease and it is frequently recommended they forego testosterone replacement therapy. We used two large phase III trials involving androgen deprivation therapy (ADT) and radiotherapy (EBRT) to assess the significance of a BST.
